BioWorld

March 19, 2007

Tracon Licenses D93 Antibody From Micromet

In a deal worth up to $100 million, Micromet Inc. licensed the preclinical anti-angiogenesis monoclonal antibody D93 to privately held Tracon Pharmaceuticals Inc. (BioWorld Today) Read More

Pfizer, Biogen Idec Launch Incubators To Build Pipelines

Alexion Gets FDA Nod For Soliris; First Drug For PNH

Trimeris Taking Back Rights To Next HIV Fusion Inhibitor

House Subcommittee Advances Genetic Discrimination Measure

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

Saniona reports preclinical data for SAN-2668

BioWorld Science

Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...

CC-3 antibody shows antitumoral activity in penile cancer

BioWorld Science

Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies...